LMLinda Mpofu-Dobo

Linda Mpofu-Dobo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linda Mpofu-Dobo has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Near-Full-Length Hepatitis B Virus Genomes Isolated from Cerebrospinal Fluid of People Living with HIV and Cryptococcal Meningitis in Botswana

    by Basetsana K. S. Phakedi, Bonolo B. Phinius, Kesaobaka Molebatsi, Nametso Kelentse, Lynnette Bhebhe, Linda Mpofu-Dobo, Kabo Baruti, Chanana Tsayang, Graceful Mulenga, Tsholofelo Sethibe, et al.

    Background/Objectives: Increasing evidence suggests that the hepatitis B virus (HBV) can be detected in extrahepatic compartments. Data on the molecular characteristics of HBV in cerebrospinal fluid (CSF) remain limited, particularly among people living with HIV (PLWH) and cryptococcal meningitis (CM). This study aimed to characterize HBV genomes from plasma and CSF and compare paired sequences for genetic similarity and potential compartment-specific differences. Methods: Archived plasma and CSF samples from PLWH with CM from Botswana enrolled in AMBITION-CM trial (2018–2021) were sequenced using Oxford Nanopore Technology to generate near-full-length HBV genomes. Genotyping and mutational analysis were performed and paired plasma–CSF sequences were compared. Results: Four sequences were generated, including one plasma–CSF pair and two CSF-only sequences. The sequences clustered with genotypes A1 and D3. The single paired plasma–CSF sequences shared 98.8% nucleotide similarity, and clustered together with strong phylogenetic support (SH-aLRT/ultrafast bootstrap = 99.6/100). Variant analysis identified 492 and 545 high-quality variants (Q ≥ 30) in plasma and CSF, respectively. In the single paired sequences, hepatocellular carcinoma (HCC)-associated mutation T1858C was detected in plasma but not in the CSF. Mutations were also identified in CSF-derived sequences, including A1762T/G1764A, G1896A, G1899A, associated with increased HCC risk, rtS184L, rtF194L, rtP236T, linked to antiviral resistance and sP127L, sQ129L, sM133L, sS136P, associated with immune escape. Conclusions: Near-full-length HBV genomes were successfully recovered and genetically characterized from the CSF of PLWH with CM. The single plasma–CSF paired sample, showed high genetic similarity and had a compartment-specific mutation. Clinically relevant mutations were observed in the CSF warranting further investigation of HBV in the CSF to confirm these observations in PLWH with CM. These preliminary findings from a limited number of participants provide a basis for larger-scale studies of near-full-length HBV genome characterization in CSF.

  • Open Access

    Deep Sequencing of Hepatitis B Virus Reveals Clinically Relevant Low-Frequency Variants Among People Living with HIV in Botswana

    by Tsholofelo Sethibe, Wonderful Tatenda Choga, Florence G. Gaongalelwe, Bonolo B. Phinius, Gorata G. A. Mpebe, Kabo Baruti, Chanana Dorcus Tsayang, Goabaone Mbae, Basetsana Katlo S. Phakedi, Patience Motshosi, et al.

    (1) Background: The Hepatitis B virus (HBV) is characterized by extensive genetic diversity, including low-frequency variants that contribute to disease progression. We aimed to characterize low-frequency variants and evaluate their potential clinical impact. (2) Methods: We utilized 104 HBV near-full-length sequences generated using next-generation sequencing (NGS) from people living with HIV (PLHIV). We used an in-house bioinformatics suite (HBVgenomeR v5.9.7) to filter for low-frequency variants (5–50%), which were compared to escape and drug resistance mutations (DRMs) and hepatocellular carcinoma (HCC)-associated mutations reported at the consensus level. Unclassified variants were characterized by HBV open reading frames (ORFs) to determine mutation frequency per genomic region. (3) Results: A total of six escape mutations were detected in 8/104 (7.7%) sequences, with surfaceN131T being the most prevalent (5/8). We also observed six DRMs in 30/104 (28.8%), with rtV173L being the most prevalent (21/30). Truncation mutations were also observed with rtA181T/sW172* and rtM204I/sW196L being the most prevalent. A total of 8/104 (7.7%) sequences had four variants associated with HCC. The xP46S was the highest observed HCC-associated mutation at 5/8. We report 1152 unique uncharacterized variants across all ORFs, and these were found in 94/104 (90.4%) sequences. The RNaseH domain had the highest burden (330/1152, 28.6%). (4) Conclusions: Deep sequencing results identified clinically significant mutations, including those below the 20% detection limit of traditional sequencing, that would go unreported. This highlights the possible underreporting of mutational burden in people living with HBV/HIV, indicating the importance of deep sequencing to aid in HBV/HIV understanding and management.

  • Open Access

    A Review of Human Immunodeficiency Virus and Hepatitis B Virus Co-Infection in Botswana

    by Linda Mpofu-Dobo, Kebaneilwe Lebani, Jason T. Blackard, Sikhulile Moyo, Motswedi Anderson, Simani Gaseitsiwe

    Hepatitis B virus (HBV) remains a leading cause of chronic liver disease worldwide, contributing to cirrhosis and hepatocellular carcinoma. Sub-Saharan Africa accounts for an estimated 68% of incident HBV infections, where co-infection with human immunodeficiency virus (HIV) is common and associated with poorer clinical outcomes. In Botswana, limited HBV screening and the absence of established HBV management guidelines persist despite reported HIV-HBV co-infection rates ranging from 1.1% to 10.6%. This scoping review aimed to summarise existing research on HBV and HIV-HBV co-infection in Botswana and assess clinical and policy implications. Following PRISMA methodology, searches were conducted across PubMed, Google Scholar, Semantic Scholar, and Consensus databases. Thirty eligible peer-reviewed studies were identified and evaluated for prevalence data, virological characteristics, genotypes, mutations, treatment outcomes, vaccination programs, and the availability of guidelines. Findings indicate intermediate-to-high HBV and HIV-HBV disease burden, substantial occult HBV infection, and gaps in diagnostic and preventive practices. The lack of routine screening, deficient infant birth-dose and adult vaccination, and established treatment pathways likely increase the risk of HBV-associated morbidity and mortality. Strengthened public health interventions, including expanded testing, enhanced vaccination coverage, and prevention of mother-to-child transmission strategies, are recommended to improve disease control and clinical outcomes in Botswana.

  • Open Access

    Hepatitis B Virus Prevalence among HIV-Uninfected People Living in Rural and Peri-Urban Areas in Botswana

    by Motswedi Anderson, Thabo Mangogola, Bonolo B. Phinius, Gorata Mpebe, Christopher O. Aimakhu, Wonderful T. Choga, Basetsana Phakedi, Lynnette N. Bhebhe, Doreen Ditshwanelo, Kabo Baruti, et al.

    (1) Background: we determined the prevalence of the hepatitis B virus (HBV) amongst people without human immunodeficiency virus (HIV) in rural and peri-urban areas in Botswana. (2) Methods: We screened for the hepatitis B surface antigen (HBsAg) from archived plasma samples of people without HIV (n = 2135) randomly selected from the Botswana Combination Prevention Program (BCPP) (2013–2018). We sequenced 415 bp of the surface region using BigDye sequencing chemistry. (3) Results: The median age of participants was 31 (IQR: 24–46) and 64% (1360/2135) were female. HBV prevalence was 4.0% (86/2135) [95% CI: 3.3–4.9]) and ranged between 0–9.2%. Older participants (>35 years) had increased odds of HBV positivity (OR: 1.94; 95% CI: [1.32–2.86]; p = 0.001). Thirteen samples were sequenced and seven (53.8%) were genotype A, three (23.1%) were genotype D and genotype E each. Clinically significant mutations were identified in the surface region, but no classic drug resistance mutations were identified. (4) Conclusions: We report an HBV prevalence of 4.0% (95% CI 3.3–4.9) among people without HIV in rural and peri-urban communities in Botswana with varying rates in different communities. A comprehensive national HBV program is required in Botswana to guide HBV prevention, testing and management.


  • Open Access

    Hepatitis B Virus Prevalence Among HIV-Uninfected People Living in Rural and Peri-Urban Areas in Botswana

    by Motswedi Anderson, Thabo Mangogola, Bonolo B. Phinius, Gorata Mpebe, Christopher O. Aimakhu, Wonderful T. Choga, Basetsana Phakedi, Lynnette N. Bhebhe, Doreen Ditshwanelo, Kabo Baruti, et al.

    (1) Background: We determined the prevalence of hepatitis B virus (HBV) amongst people without human immunodeficiency virus (HIV) in rural and peri-urban areas in Botswana. (2) Methods: We screened hepatitis B surface antigen (HBsAg) from archived plasma samples of people without HIV (n=2135) randomly selected from the Botswana Combination Prevention Program (BCPP) (2013–2018). We sequenced 415 bp of the surface region using BigDye sequencing chemistry. (3) Results: The median age of participants was 31 (IQR: 24–46) and 64% (1360/2135) were female. HBsAg prevalence was 4.0% (86/2135) [95% CI: 3.3 – 4.9]) and ranged between 0%–9.2%. Older participants (>35 years) had increased odds of HBsAg positivity (OR: 1.94; 95% CI: [1.32–2.86]; p = 0.001. Thirteen samples were sequenced and 7 (53.8%) were genotype A, 3 (23.1%) were genotype D and genotype E each. Clinically significant mutations were identified in the surface region, but no classic drug resistance mutations were identified. (4) Conclusions: We report an HBV prevalence of 4.0% (95% CI 3.3 – 4.9) among people without HIV in rural and pe-ri-urban communities in Botswana with varying rates in different communities. A comprehen-sive national HBV program is required in Botswana to guide HBV prevention, testing and management.